Amyris (AMRS) Receives Daily News Impact Score of 0.19

Press coverage about Amyris (NASDAQ:AMRS) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amyris earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.1222428826594 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Several analysts have recently issued reports on the stock. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the company a “buy” rating in a research note on Wednesday, November 29th. Cowen reissued a “hold” rating and set a $4.00 price objective on shares of Amyris in a research note on Wednesday, November 29th. ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Amyris has an average rating of “Hold” and a consensus price target of $20.69.

Shares of Amyris (AMRS) traded up $0.05 during trading on Friday, reaching $3.75. 134,484 shares of the company were exchanged, compared to its average volume of 254,161. The company has a current ratio of 0.92, a quick ratio of 0.82 and a debt-to-equity ratio of -0.78. Amyris has a 12-month low of $1.86 and a 12-month high of $12.45. The stock has a market cap of $160.95, a PE ratio of -0.61 and a beta of 0.16.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The company had revenue of $24.20 million for the quarter, compared to analysts’ expectations of $36.30 million. During the same period last year, the business posted ($0.07) earnings per share. The company’s revenue for the quarter was down 8.8% compared to the same quarter last year. analysts predict that Amyris will post -3.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

What are top analysts saying about Amyris? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit